Published online April 2, 2007
PEDIATRICS Vol. 119 No. 4 April 2007, pp. 838-845 (doi:10.1542/10.1542/peds.2007-0273)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

POLICY STATEMENT

Increasing Antiretroviral Drug Access for Children With HIV Infection

Committee on Pediatric AIDS, Section on International Child Health

Although there have been great gains in the prevention of pediatric HIV infection and provision of antiretroviral therapy for children with HIV infection in resource-rich countries, many barriers remain to scaling up HIV prevention and treatment for children in resource-limited areas of the world. Appropriate testing technologies need to be made more widely available to identify HIV infection in infants. Training of practitioners in the skills required to care for children with HIV infection is required to increase the number of children receiving antiretroviral therapy. Lack of availability of appropriate antiretroviral drug formulations that are easily usable and inexpensive is a major impediment to optimal care for children with HIV. The time and energy spent trying to develop liquid antiretroviral formulations might be better used in the manufacture of smaller pill sizes or crushable tablets, which are easier to dispense, transport, store, and administer to children.

Key Words: HIV • children • antiretroviral therapy • drug formulations

Abbreviations: ARV—antiretroviral • ART—antiretroviral therapy • PEPFAR—President's Emergency Plan for AIDS Relief • WHO—World Health Organization • FDA—Food and Drug Administration • FDC—fixed-dose combination


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 AAP NewsHome page
S. Cash
Breaking down barriers: At least 2.3 million children were living with perinatally acquired HIV infection at the end of 2005, most of them in sub-Saharan Africa. A new AAP policy statement, endorsed by organizations worldwide, offers solutions to providing antiretroviral access to children globally.
AAP News, April 1, 2007; 28(4): 15 - 15.
[Full Text] [PDF]